OncoBeta

OncoBeta has developed the world-first epidermal radioisotope therapy for the effective treatment of non-melanoma skin cancers, including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), offering a groundbreaking treatment option for patients with non-melanoma skin cancer (NMSC) – the world’s most prevalent cancer. Rhenium-SCT® utilizes the Beta emitter radioisotope Rhenium-188 to painlessly treat NMSC, without the need for invasive surgery, therefore providing positive aesthetic outcomes. In most cases, treatment with Rhenium-SCT only requires one quick, personalized treatment.

OncoBeta is committed to changing the way people think about NMSC treatment, leading the field in innovation, and improving patients’ quality of life.